Clarivate

OCTOBER 19, 2023

Drug candidates have a high rate of failure, as only 10% of de-novo drugs put through clinical trials finally obtain market approval, with the highest rate of attrition occurring at phase I and II of clinical trials (assessing safety, tolerability, dosage, efficacy, and side effects).

Networking 59

Networking Consulting Safety Side effects 59

Clarivate

OCTOBER 25, 2023

exclusions exist for orphan drug designation and biosimilar competition ). Expect some provider practices to research using alternative treatments not subject to price negotiations for their new patients, assuming comparable efficacy, safety, and tolerability (e.g.,

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

OCTOBER 10, 2022

Fruquintinib will face fierce competition should it be approved in the third- and later-line setting. Fruquintinib was well-tolerated, with a safety profile consistent with that previously reported in other studies. Hutchmed´s fruquintinib is a highly selective and potent oral inhibitor of VEGFR1-3. months; HR: 0.321, P<0.001).

Marketing 52

Marketing Safety Patients Competition 52

Pharmaceutical Technology

DECEMBER 20, 2022

Maintaining sterility is critical in the final steps of parenteral drug processing, ensuring doses are free from microbial contamination that could affect patient safety. McCall sees the whole experience as a positive one for biopharma: “When I started in industry, this type of data sharing and collaboration was unheard of.

Biopharma 52

Biopharma Manufacturing FDA Pharmaceutical 52

PM360

SEPTEMBER 28, 2022

Now, as the President of Accord BioPharma , the U.S. PM360: From your time at Roche when you were dealing with biosimilars as potential competition to now leading the launch of biosimilars at Accord and Intas, how have you seen the marketplace for biosimilars evolve over that time? Look, competition is healthy.

Competition 98

Competition Marketing Biopharma Manufacturing 98

Clarivate

MARCH 12, 2024

For the approximately 10% of biopharma candidates that actually manage to make it to clinical trials, many fail to achieve enough revenue once they reach the market to justify the R&D effort. In fact, one-third of drugs launched over a recent 10-year period fell short of sales expectations.

Government 52

Government Physicians Marketing Biopharma 52

European Pharmaceutical Review

DECEMBER 26, 2023

The increasing adoption of technologies promoting safety, efficacy and reduced production costs has been a persistent trend that will continue to benefit the industry and help to treat a broader patient population. million for Hemgenix [AAV5-hFIX-Padua]). million for Hemgenix [AAV5-hFIX-Padua]).

Manufacturing 87

Manufacturing Safety Patients Competition 87

Clarivate

OCTOBER 7, 2021

What’s new from ESMO: Interim efficacy and safety analysis from the randomized KEYNOTE-716 study showed that the trial met its primary endpoint of RFS, with patients receiving Keytruda presenting an RFS of 90.5% This novel antibody-drug conjugate (ADC)ADC faces much competition, should it be approved. at 12-months compared to 83.1%

Patients 91

Patients Safety Marketing Physicians 91

Clarivate

DECEMBER 1, 2021

Treatment cost and compliance are key factors in sustaining effective long-term disease management, a powerful new oral option could be more widely accepted than the injectable competition and rapidly gain traction in the market, especially among primary care physicians. Contributors. Circulation 2021; 144(suppl1): LBS.05. Perin EC, et al.

Safety 52

Safety Patients Management Marketing 52